Physician profile
Jayla Gray
NPI 1053706911
$2,825.18
in general payments reported to CMS, 2019-2025
18 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2021: $403 · 2022: $176 · 2023: $517 · 2024: $405 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845 · Education: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.84 |
| Education | $304.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $613.29 | 2021-2025 | |
| Genzyme Corporation | $287.77 | 2022-2025 | |
| Amgen INC. | $275.49 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $251.08 | 2023-2024 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $247.24 | 2021-2025 | |
| Leo Pharma INC. | $194.83 | 2022-2025 | Adbry |
| Incyte Corporation | $186.42 | 2021-2023 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $155.87 | 2022-2025 | Dupixent |
| Galderma Laboratories, L.P. | $148.90 | 2021-2025 | Nemluvio |
| Pfizer INC. | $110.46 | 2023-2025 | |
| Allergan, INC. | $97.33 | 2019 | |
| Lilly USA, LLC | $96.63 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.30 | 2025 | Cabtreo |
| Sun Pharmaceutical Industries INC. | $26.37 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.71 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $22.24 | 2023 | |
| Ucb, INC. | $20.92 | 2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $18.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayla Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.